RAPT Therapeutics Inc

NASDAQ RAPT

Data sourced from

and

Download Data

RAPT Therapeutics Inc Payables Turnover 5 year CAGR for the quarter ending March 31, 2024

RAPT Therapeutics Inc Payables Turnover 5 year CAGR is NA for the quarter ending March 31, 2024. Payables turnover measures the efficiency with which a company manages its accounts payable. It is calculated by dividing the cost of revenue by the accounts payable. This ratio indicates how quickly a company pays off its obligations to suppliers and vendors. A higher turnover suggests that the company is efficiently managing its accounts payable, while a lower ratio may indicate a slower payment process or potential liquidity issues. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

RAPT Therapeutics Inc Payables Turnover for the quarter ending March 31, 2023 was 0.10.

NASDAQ: RAPT

RAPT Therapeutics Inc

CEO	Dr. Brian Russell Wong M.D., Ph.D.
IPO Date	Oct. 31, 2019
Location	United States
Headquarters	561 Eccles Avenue, South San Francisco, CA, United States, 94080
Employees	126
Sector	Healthcare
Industry	Biotechnology

Description

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Key trends